Bernhard Kirschbaum

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.